Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for
CACNA1C
CHRNA7
Deep phenotyping
MAPK1
Major depressive disorder
Journal
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
ISSN: 1738-1088
Titre abrégé: Clin Psychopharmacol Neurosci
Pays: Korea (South)
ID NLM: 101207332
Informations de publication
Date de publication:
31 Aug 2019
31 Aug 2019
Historique:
received:
29
11
2017
accepted:
04
12
2017
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
30
7
2019
Statut:
ppublish
Résumé
Genetics factors are likely to play a role in the risk, clinical presentation and treatment outcome in major depressive disorder (MDD). In this study, we investigated the role of three candidate genes for MDD; calcium voltage- gated channel subunit alpha1 C ( CACNA1C ), cholinergic receptor nicotinic alpha 7 subunit ( CHRNA7 ), and mitogen- activated protein kinase 1 ( MAPK1 ). Two-hundred forty-two MDD patients and 326 healthy controls of Korean ancestry served as samples for the analyses. Thirty-nine single nucleotide polymorphisms (SNPs) within CACNA1C , CHRNA7 , and MAPK1 genes were genotyped and subsequently tested for association with MDD (primary analysis) and other clinical features (symptoms' severity, age of onset, history of suicide attempt, treatment outcome) (secondary analyses). Single SNPs, haplotypes and epistatic analyses were performed. Single SNPs were not associated with disease risk and clinical features. However, a combination of alleles (haplotype) within MAPK1 was found associated with MDD-status. Secondary analyses detected a possible involvement of CACNA1C haplotype in resistance to antidepressant treatment. These data suggest a role for MAPK1 and CACNA1C in MDD risk and treatment resistance, respectively. However, since many limitations characterize the analysis, the results must be considered with great caution and verified.
Identifiants
pubmed: 31352702
pii: cpn.2019.17.3.364
doi: 10.9758/cpn.2019.17.3.364
pmc: PMC6705106
doi:
Types de publication
Journal Article
Langues
eng
Pagination
364-368Références
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Mol Psychiatry. 2002;7(6):525-35
pubmed: 12140772
Eur J Biochem. 2004 Jun;271(11):2050-5
pubmed: 15153093
Bioinformatics. 2005 Jan 15;21(2):263-5
pubmed: 15297300
Stroke. 2005 Sep;36(9):1879-80
pubmed: 16120843
Psychopharmacology (Berl). 2006 Dec;189(3):395-401
pubmed: 17016705
Am J Psychiatry. 2010 Nov;167(11):1305-20
pubmed: 20843874
Prog Neurobiol. 2011 Sep 1;94(4):418-60
pubmed: 21723912
Curr Drug Targets. 2012 May;13(5):602-6
pubmed: 22300026
Eur Neuropsychopharmacol. 2012 Jul;22(7):453-68
pubmed: 22464339
Curr Top Behav Neurosci. 2013;14:135-51
pubmed: 22553073
Transl Psychiatry. 2012 Feb 21;2:e79
pubmed: 22832816
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:271-8
pubmed: 23537502
J Affect Disord. 2013 Sep 5;150(2):384-8
pubmed: 23759278
Br J Psychiatry. 2014 Jan;204(1):36-9
pubmed: 24262814
Cell Tissue Res. 2014 Aug;357(2):463-76
pubmed: 24996399
Neuroscience. 2014 Sep 26;277:541-51
pubmed: 25075716
BMC Psychiatry. 2016 Apr 18;16:106
pubmed: 27091189
Am J Med Genet B Neuropsychiatr Genet. 2016 Sep;171(6):896-903
pubmed: 27260792
Nat Rev Dis Primers. 2016 Sep 15;2:16065
pubmed: 27629598
Clin Psychopharmacol Neurosci. 2017 Feb 28;15(1):53-58
pubmed: 28138111
Neuropsychobiology. 2016;74(3):159-168
pubmed: 28494468
Mol Psychiatry. 2018 Mar;23(3):533-543
pubmed: 28696432
Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):1-6
pubmed: 29397661
Psychol Med. 1985 Nov;15(4):745-58
pubmed: 3909185
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538